SIU Congress 2016: Challenging cases in bladder cancer: High grade T1 bladder cancer: New promising alternatives for patients who fail BCG immunotherapy - Session Highlights


Buenos Aires, Argentina (UroToday.com) Yves Fradet, Professor University of Laval, discussed definitions of BCG failure including refractory, relapsing and intolerant BCG failures. Not all BCG strains are equivalent and need to be taken into consideration.


BCG vs BCG/IFN randomized trial was negative, however, 45% prior BCG failures were responsive to BCG/IFN combination therapy. Additional immunotherapy combinations are being considered including anti-PDL-1, anti-PD1 and anti-CTLA4 immune checkpoint inhibitors. These inhibitors have been successful with even complete response in patients with metastatic bladder cancer with or without prior chemotherapy treatment. Electromotive MMC has been shown to have decreased progression with improved survival when combined with BCG vs. BCG alone. Concentration of MC, alkalization and ensuring bladder empty prior to instillation will optimize MMC delivery with improved oncologic efficacy. MMC hyperthermia are other alternatives to enhance delivery of MMC with results pending.

World Urological Oncology Federation Symposium at the SIU Congress 2016 - October 20 - 23, 2016 – Buenos Aires, Argentina

Written By: Stephen B. Williams, M.D., Assistant Professor in Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe